scholarly journals Risk of venous thromboembolism in Asian patients with inflammatory bowel disease: a nationwide cohort study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chan Mi Heo ◽  
Tae Jun Kim ◽  
Eun Ran Kim ◽  
Sung Noh Hong ◽  
Dong Kyung Chang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
Incidence Rate ◽  
Older Patients ◽  
Age Groups ◽  
Young Patients ◽  
Incidence Rates ◽  
Patient Specific ◽  
Bowel Surgery ◽  
Asian Patients

AbstractRoutine prophylaxis for venous thromboembolism (VTE) in Asian IBD patients has been controversial. We aimed to estimate the risk of VTE of Asian patients at different phases of IBD by incorporating patient-specific risk factors. In this cohort study, we analyzed the National Health Insurance claims data between 2012 and 2016 for the entire Korean population. We calculated incidence rates and hazard ratios for VTE. The overall VTE risk was higher in patients with IBD [adjusted hazard ratio (aHR), 2.06; 95% confidence interval (CI), 1.66–2.55], than in controls. When we compare the risk of VTE by different disease phases, the risk of VTE was the highest during post-operation period after IBD-related bowel surgery (aHR, 39.7; 95% CI 9.87–159.3), followed by during hospitalized periods with flare (aHR, 27.2; 95% CI 14.9–49.65) and during hospitalized periods with non-flare (aHR, 16.23; 95% CI 10.71–24.58). The incidence rate (per 1000 person-years) was 15.26 during hospitalized periods with a flare and 9.83 during hospitalized periods with non-flare. According to age groups, the incidence rate (per 1000 person-years) during hospitalized periods with flare was 14.53 in young patients (20–39 years) and 34.58 in older patients (60–80 years). During hospitalized periods with non-flare, the incidence rate was 3.55 in young patients and 23.61 in older patients. The prophylaxis of VTE for Asian patients with IBD should be recommended in older patients admitted to hospital and be considered in young patients who are hospitalized with a flare.

Temporal Incidence Trends of Pediatric Venous Thromboembolism: A Population-Based Cohort Study

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1138-1138
Author(s):  
Christine A. Sabapathy ◽  
Susan R. Kahn ◽  
Robert W Platt ◽  
Vicky Tagalakis
Keyword(s):  
Sex Differences ◽  
Venous Thromboembolism ◽  
Incidence Rate ◽  
Conflicts Of Interest ◽  
Age Groups ◽  
Incidence Rates ◽  
Age Group ◽  
Incidence Trends ◽  
Incident Cases ◽  
Temporal Incidence

Abstract Abstract 1138 Background: Pediatric venous thromboembolism (VTE), although rare, is associated with significant morbidity and mortality. Published incidence rates in this age group vary from 0.07 to 0.49 VTE per 10 000 children/year and there is currently a paucity of studies evaluating temporal incidence trends. Objectives: To describe the age-adjusted incidence rates of pediatric VTE and its trend over time in a large pediatric cohort. Methods: A retrospective cohort of all children (ages 1–17 inclusive) with a first time diagnosis of VTE in the province of Quebec, Canada over an eleven-year period, from January 1st, 1994 to December 31st, 2004, was obtained from a comprehensive administrative hospital database (Med-Echo). Quebec census estimates were used to calculate age-standardized incidence rates (IR) of pediatric VTE. The incidence rate trend was then analyzed over the eleven-year study period using Poisson linear regression. Sex differences in incidence rates at the population level stratified by age group as a confounder as well as baseline characteristics of the cases were also evaluated. Results: In total, 487 incident cases of VTE in children 1–17 years of age were documented during the study period. Based on the estimated provincial census person-years during the study period, the age-standardized IR was 0.29 VTE per 10 000 person-years (95% confidence interval (CI) 0.26–0.31). Females overall had a statistically significant higher VTE incidence rate with an incidence rate ratio of 1.75 (95% CI 1.46–2.11) when controlled for age groups, as compared to males. When analyzed by age group, the age-standardized IRs were as follows: 1–5 year olds 0.04 VTE per 10 000 person-years (95% CI 0.03–0.05); 6–10 year olds 0.03 VTE per 10 000 person-years (95% CI 0.02–0.04); 11–14 year olds 0.06 VTE per 10 000 person-years (95% CI 0.05–0.07); 15–17 year olds 0.16 VTE per 10 000 person-years (95% CI 0.14–0.18). Trend analysis of the age-standardized IRs over the 11-year period showed no significant change in incidence rates whether using time as a continuous (yearly) or categorical variable (time-periods). Conclusions: Pediatric VTE is more frequent than previously described, however the rate is stable. As shown by others, children in their late-teen years have a higher risk of VTE than primary school-aged children. Unlike prior studies, females were more prone to VTE than males. Future studies that address sex differences in the incidence of pediatric VTE are needed to help determine effective primary thromboprophylaxis strategies in children at high risk for VTE. Disclosures: No relevant conflicts of interest to declare.

The Incidence of Hospital-Treated Occupational Hand Injuries

1994 ◽  
Vol 19 (1) ◽  
pp. 118-119 ◽  
Author(s):  
O. SKOV
Keyword(s):  
Incidence Rate ◽  
Selection Bias ◽  
Older Patients ◽  
Age Groups ◽  
Young Patients ◽  
Young Men ◽  
Hand Injuries ◽  
Minor Injuries ◽  
Age And Sex

Previous studies have shown that young men have the highest frequency of occupational hand injuries. This study investigated their incidence and severity in relation to age and sex. For occupational hand injuries in general the estimated incidence rate was 17.1 per 1,000 person years. The incidence was found to be higher among men than women in all age groups below 60 years. The incidence for minor injuries declines with increasing age, but the rates for significant injuries are independent of age. The higher incidence rate for minor injuries among young patients could be real, but it could also be partly due to selection bias, if older patients with minor injuries consult the hospital for treatment less frequently.

scholarly journals Geographical variation and clustering are found in atrial fibrillation beyond socioeconomic differences: a Danish cohort study, 1987–2015

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Kirstine Wodschow ◽  
Kristine Bihrmann ◽  
Mogens Lytken Larsen ◽  
Gunnar Gislason ◽  
Annette Kjær Ersbøll
Keyword(s):  
Risk Factors ◽  
Atrial Fibrillation ◽  
Cohort Study ◽  
Incidence Rate ◽  
Socioeconomic Position ◽  
Geographical Variation ◽  
Incidence Rates ◽  
Socioeconomic Differences ◽  
Individual Level ◽  
Geographical Variations

Abstract Background The prevalence and incidence rate of atrial fibrillation (AF) increase worldwide and AF is a risk factor for more adverse cardiovascular diseases including stroke. Approximately 44% of AF cases cannot be explained by common individual risk factors and risk might therefore also be related to the environment. By studying geographical variation and clustering in risk of incident AF adjusted for socioeconomic position at an individual level, potential neighbourhood risk factors could be revealed. Methods Initially, yearly AF incidence rates 1987–2015 were estimated overall and stratified by income in a register-based cohort study. To examine geographical variation and clustering in AF, we used both spatial scan statistics and a hierarchical Bayesian Poisson regression analysis of AF incidence rates with random effect of municipalities (n = 98) in Denmark in 2011–2015. Results The 1987–2015 cohort included 5,453,639 individuals whereof 369,800 were diagnosed with an incident AF. AF incidence rate increased from 174 to 576 per 100,000 person-years from 1987 to 2015. Inequality in AF incidence rate ratio between highest and lowest income groups increased from 23% in 1987 to 38% in 2015. We found clustering and geographical variation in AF incidence rates, with incidence rates at municipality level being up to 34% higher than the country mean after adjusting for socioeconomic position. Conclusions Geographical variations and clustering in AF incidence rates exist. Compared to previous studies from Alberta, Canada and the United States, we show that geographical variations exist in a country with free access to healthcare and even when accounting for socioeconomic differences at an individual level. An increasing social inequality in AF was seen from 1987 to 2015. Therefore, when planning prevention strategies, attention to individuals with low income should be given. Further studies focusing on identification of neighbourhood risk factors for AF are needed.

Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer

2014 ◽  
Vol 112 (08) ◽  
pp. 255-263 ◽  
Author(s):  
Alexander T. Cohen ◽  
Luke Bamber ◽  
Stephan Rietbrock ◽  
Carlos Martinez
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
The Elderly ◽  
Population Based ◽  
Incidence Rates ◽  
Practice Research ◽  
Clinical Practice Research Datalink ◽  
Recurrence Rates ◽  
Recurrent Vte ◽  
Active Cancer

SummaryContemporary data from population studies on the incidence and complications of venous thromboembolism (VTE) are limited. An observational cohort study was undertaken to estimate the incidence of first and recurrent VTE. The cohort was identified from all patients in the UK Clinical Practice Research Datalink (CPRD) with additional linked information on hospitalisation and cause of death. Between 2001 and 2011, patients with first VTE were identified and the subset without active cancer-related VTE observed for up to 10 years for recurrent VTE. The 10-year cumulative incidence rates (CIR) were derived with adjustment for mortality as a competing risk event. A total of 35,373 first VTE events (12,073 provoked, 16,708 unprovoked and 6592 active cancer-associated VTE) among 26.9 million person-years of observation were identified. The overall incidence rate (IR) of VTE was 131.5 (95% CI, 130.2–132.9) per 100,000 person-years and 107.0 (95% CI, 105.8–108.2) after excluding cancer-associated VTE. DVT was more common in the young and PE was more common in the elderly. VTE recurrence occurred in 3671 (CIR 25.2%). The IR for recurrence peaked in the first six months at around 11 per 100 person years. It levelled out after three years and then remained at around 2 per 100 person years from year 4–10 of follow-up. The IRs for recurrences were particularly high in young men. In conclusion, VTE is common and associated with high recurrence rates. Effort is required to prevent VTE and to reduce recurrences.

scholarly journals Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study

2021 ◽  
Author(s):  
Milou Ohm ◽  
Susan J M Hahné ◽  
Arie van der Ende ◽  
Elizabeth A M Sanders ◽  
Guy A M Berbers ◽  
...  
Keyword(s):  
The Netherlands ◽  
Incidence Rate ◽  
Vaccination Programme ◽  
Screening Method ◽  
Age Groups ◽  
Incidence Rates ◽  
Age Group ◽  
Mass Campaign ◽  
Conjugate Vaccination ◽  
The Impact

Abstract Background In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for 14-month-olds was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting 14-18 year-olds was executed. We investigated the impact of MenACWY vaccination implementation in 2018-2020 on incidence rates and estimated vaccine effectiveness (VE). Methods We extracted all IMD cases diagnosed between July 2014 and December 2020 from the national surveillance system. We calculated age group-specific incidence rate ratios by comparing incidence rates before (July 2017-March 2018) and after (July 2019-March 2020) MenACWY vaccination implementation. We estimated VE in vaccine-eligible cases using the screening method. Results Overall, IMD-W incidence rate lowered by 61% (95%CI 40-74). It declined by 82% (95%CI 18-96) in vaccine-eligible age group (15-36 month-olds and 14-18 year-olds) and by 57% (95%CI 34-72) in vaccine non-eligible age groups. VE was 92% (95%CI -20-99.5) against IMD-W vaccine-eligible toddlers. No IMD-W cases were reported in vaccine-eligible teenagers after the campaign. Conclusions The MenACWY vaccination programme was effective in preventing IMD-W in the target population. The IMD-W incidence reduction in vaccine non-eligible age groups may be caused by indirect effects of the vaccination programme. However, disentangling natural fluctuation from vaccine-effect was not possible. Our findings encourage the use of toddler- and teenager MenACWY vaccination in national immunization programmes especially when implemented together with a teenager mass campaign during an epidemic.

Higher Incidence of Chronic Myeloid Leukemia (CML) Among Blacks Compared to Whites in the Post-Imatinib Period (2002–2009) Corresponds with Worse Survival Observed within the Surveillance, Epidemiology and End Results 18 Registries

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3773-3773
Author(s):  
Adam Mendizabal ◽  
Paul H Levine
Keyword(s):  
Tyrosine Kinase ◽  
Incidence Rate ◽  
Kinase Inhibitors ◽  
Age Groups ◽  
Incidence Rates ◽  
Age At Diagnosis ◽  
Age Group ◽  
Risk Of Death ◽  
Younger Age ◽  
Adjusted Incidence

Abstract Abstract 3773 Background: Age at diagnosis of CML varies by race in the United States with median occurring around ages 54 and 63 among Black and White patients, respectively. The treatment paradigm shifted when Imatinib was approved in 2001 for treatment of CML. More recently, second generation tyrosine kinase inhibitors (TKI) have also been used for treatment of CML. Differences in outcomes by race have been previously reported prior to the TKI treatment period. We aimed to assess whether the earlier age at diagnosis resulted in differential trends in age-adjusted incidence rates and survival outcomes by race in the post-Imatinib treatment period. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) 18 Registries were extracted for diagnoses between 2002 and 2009 based on the assumption that cases diagnosed after 2002 would be treated with TKI's. CML was defined according to the International Classification of Diseases for Oncology 3rd edition code 9863 (CML-NOS) and 9875 (CML-Philadelphia Chromosome Positive). Cases diagnosed by autopsy or death certificate only were excluded. Incidence rates are expressed per 100,000 person-years and age-adjusted to the 2000 US Standard Population. Black/White incidence rate ratios (IRRBW) are shown with corresponding 95% confidence intervals (CI). Kaplan-Meier estimates of CML-specific survival (CPS) and overall survival (OS) were estimated at 5-years post-diagnosis with the event being time to CML-specific death or any death, respectively. Stratified Cox proportional hazards models were constructed to assess the impact of age and race on the risk of death expressed as a hazard ratio (HR). Results: Since 2002, 6,632 patients diagnosed with CML were reported to the SEER 18 registries including 5,829 White patients (87.9%) and 803 Black patients (12.1%) with 57% being male. The age-adjusted incidence rate for Blacks was 1.18 (95% CI, 1.10–1.27) per 100,000 and 1.12 (95% CI, 1.09–1.27) per 100,000 for Whites. The corresponding IRRBW was 1.06 (95% CI, 0.98– 1.14). When considering 20-year age-groups, Blacks had higher incidence rates in the 20–39 and 40–59 age groups; IRRBW of 1.26 (95% CI, 1.06–1.49; p=0.0073) and 1.23 (95% CI, 1.09–1.39; p=0.0007), respectively. No statistically significant differences in IRRBW were seen within the 0–19, 60–79 and 80+ age-groupings although Whites have higher non-significant incidence rates in the latter 2 age-groups. Differences in IRRBW prompted an assessment of survival to determine if the excess incidence observed in the younger age groups corresponded with a worse survival. CPS at 5-years was 85.5% (95% CI, 84.3–86.6). In univariate analysis, age was an important predictor of outcome (p<0.0001) with patients diagnosed after age 80 having the worse outcomes (OS: 58.3%), followed by patients diagnosed between 60 and 79 years (OS 84.7%), 0–19 years (OS: 87.1%), 40–59 years (OS: 90.2%), and 20–39 years (OS: 92.6%). When considering all age-groups, race was not a significant predictor of death (HR 0.91; 95% CI, 0.72–1.15). However, in a stratified analysis with 20-year age groups, Blacks had an increased risk of death as compared to Whites (Figure 1) in the 20–39 age group (HR: 2.94; 95% CI, 1.72–5.26; p<0.0001) and the 40–59 age group (HR: 1.67; 95% CI, 1.22–2.27; p=0.0069) while no differences were seen within the 0–19, 60–79 and 80+ age groups. Conclusions from OS models were similar to that of the CPS models. Conclusions: Through this analysis of population-based cancer registry data collected in the US between 2002 and 2009, we show that Blacks have a younger age at diagnosis with higher incidence rates observed in the 20–39 and 40–59 age-groups as compared to Whites. Both CPS and OS outcomes differed by race and age. Similar to the differences observed with the incidence rates, survival was worse in Blacks diagnosed within the 20–39 and 40–59 age-groups as compared to Whites. Although outcomes have globally improved in patients with CML since the advent of tyrosine kinase inhibitors, the persistence of incidence heterogeneity and poorer survival among Blacks warrants further attention. Access to care may be a possible reason for the differences observed but further studies are warranted to rule out biological differences which may be causing an earlier age at onset and poorer survival. Disclosures: No relevant conflicts of interest to declare.

Breast cancer incidence in a large cohort of Peruvian women affiliated to a pre-paid system.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12570-e12570
Author(s):  
Juan F. Suazo ◽  
Priscila I. Valdiviezo ◽  
Claudio J. Flores ◽  
Jorge Iberico ◽  
Joseph A. Pinto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
At Risk ◽  
General Population ◽  
Incidence Rate ◽  
Breast Cancer Incidence ◽  
Age Groups ◽  
Cumulative Risk ◽  
Incidence Rates ◽  
Specific Rate ◽  
Age Group

e12570 Background: Breast cancer (BC) is the second most common malignancy and the leading cause of death by cancer in Peruvian women (age-standarized rate [ASR] of 34 new cases/100,000 women estimated by GLOBOCAN 2008). The purpose of this study was to assess the incidence of BCin acohort ofwomenat Oncosalud, an oncologic pre-paid system that currently has 600,000 affiliates. Methods: We evaluated a dynamic cohort (period 1989 to 2011) of women affiliatedat Oncosalud – AUNA, an oncologic prepaid system.The crude incidence rate per year (number of new cases/women at risk), the specific rate according to age (number of new cases / persons-year) and cumulative risk were calculated. Results: Overall, during the assessment period, the BC incidence rate per year was 175.6 and the ASR incidence was 111.9 per 100,000 affiliates respectively. In our cohort of affiliates there were no BC cases before 1993 (with 907 women at risk for that year). The highest incidence rate was 177.6 registered in 1997 (11,822 women at risk). Incidence rates started decreasing in 2003 (169.2 with a population at risk of 39,593 women). The lowest incidence was 71.5, registered in 2011 (279,680 women at risk).According to age-groups, there were no BC cases under20 years old. Specificincidence ratesper age-group increases from the 30 year old-group (55.8). The peak of BC incidence was between 70 to 74 years old (407.4). In the same way, the cumulative risk increases after 30 years old. Conclusions: In our cohort of affiliates, the incidence of BC is greater than the general population, it could be due to the process of negative selection; however, specific incidence rates per age-group and cumulative risk are increased after 30 years, as seen in the general population.

Evolving prevalence and incidence trends of SCC of the anal canal: A SEER study.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 583-583 ◽  
Author(s):  
Shunqing Zhang ◽  
Thomas A. DiPetrillo ◽  
Kara Lynne Leonard
Keyword(s):  
Anal Canal ◽  
Incidence Rate ◽  
Age Groups ◽  
Young Patients ◽  
Black Population ◽  
Racial Groups ◽  
Data Set ◽  
Incidence Trends ◽  
Indian American ◽  
Race Ethnicity

583 Background: The incidence of squamous cell carcinoma of the anal canal (SCCA) has been rising in the last three decades. With changing patient demographics and behaviors, the trends in prevalence and incidence of the disease have changed in recent years. Methods: The Surveillance, Epidemiology, and End Results (SEER) data set from 2000 to 2014 was analyzed for trends in prevalence and incidence of SCCA and for associated demographic and tumor characteristics including stage (localized vs. regional vs. distant disease), age (20-34, 35-49, 50-64, > 65 years), and race/ethnicity (White, Black, American Indian/American Natives (AI/AN), American Pacific Islanders (API)). Results: 16,540 patients with SCCA were identified in the SEER database within the study period. The prevalence rate of SCCA was 0.01% (of 2000 standard U.S population), and the age-adjusted incidence rate of SCCA was 1.3/100,000. Prevalence and incidence was highest in patients age 50-64 and in the black population. Trend analysis of incidence demonstrated that while incidence rate continued to increase from 2000 to 2014, the average annual percentage change (APC) of incidence decreased from 4.80 before 2009 to 1.44 after. Patient population was divided into two groups: 2000-2008, with incidence of 1.6/100,000 and 2009-2014, with incidence of 2.1/100,000 (RR = 1.29, 95%CI = 1.25-1.33, p < 0.001). Incidence in the 2009-2014 group increased compared to the 2000-2008 group among all staged SCCA, patients 50 years of age and older (RR = 1.41, p < 0.001 and RR = 1.37, p < 0.001 for age groups 50-64 and > 65, respectively), and black (RR = 1.33, p < 0.001) and white (RR = 1.32, p < 0.001) race/ethnicity groups. APC in the 2009-2014 group decreased in all staged SCCA, increased in patients age 20-34, and decreased in all racial groups except AI/AN. Conclusions: There is a higher incidence and prevalence of SCCA in patients 50 years or older and in those of black ethnicity. Incidence of SCCA has increased in the US from 2000-2014, but the average APC in incidence has been decreasing except for in young patients and in those of AI/AN ethnicity. Awareness of disease prevalence and the pattern of change in incidence rate is important in the effort of disease prevention.

scholarly journals Osteosarcoma: A Comparison of Jaw versus Nonjaw Localizations and Review of the Literature

Sarcoma ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
H. van den Berg ◽  
W. H. Schreuder ◽  
J. de Lange
Keyword(s):  
Older Patients ◽  
Age Groups ◽  
Incidence Rates ◽  
Steady Increase ◽  
Review Of The Literature ◽  
Tumor Patients ◽  
Age Cohorts ◽  
Age Cohort ◽  
Steep Decline ◽  
Age Range

Purpose. It is assumed that osteosarcomas of the jaws mainly occur at older ages, whereas the most prominent sites, that is, the long bones, are more affected at ages <20. Jaw-localized tumors are less malignant and have lower metastatic spread rates.Patients and Methods. This study analyses the nationwide data of the Dutch Cancer Registry on osteosarcoma during the period from 1991 to 2010. Age-corrected incidence rates were calculated.Results. In 949, 38 patients had tumors in the maxilla and in 58 in the mandible. Median age for maxilla, mandible, and other localizations was 45.5, 49, and 23 years, respectively. Age-corrected incidence for osteosarcomas increased after a steep decline for the age cohorts from 20 to 60 years to nearly the same level as the younger patients. The incidence for maxillary lesions showed a steady increase from 0.46 to 1.60 per million over all age ranges; the highest incidence for mandibular lesions was found in the age cohort from 60 to 79 years. In respect to histology, no shifts for age were found, except for Paget’s disease-related osteosarcoma. In older patients, chemotherapy was omitted more often. Overall survival was similar for all age groups, except for extragnatic tumor patients in the age range of 60–79 years.Conclusions. Osteosarcomas have comparable incidences below the age of 20 as compared with ages >60 years. Poorer outcome in older people is likely due to refraining from chemotherapy.

scholarly journals Evaluating the Effect of Ethnicity on the Risk of Venous Thromboembolism (VTE): A Systematic Review

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4714-4714
Author(s):  
Fatimah Al-Ani ◽  
Yo-Liang Teng ◽  
Alla Iansavichene ◽  
Alejandro Lazo-Langner
Keyword(s):  
Venous Thromboembolism ◽  
Incidence Rate ◽  
Ethnic Groups ◽  
American Indians ◽  
Geographical Area ◽  
Significant Risk ◽  
Population Based ◽  
Incidence Rates ◽  
Discharge Data ◽  
Incidence Prevalence

Abstract Background Studies of hospital discharge data and large observational cohorts show that the incidence of venous thromboembolism (VTE) varies by race. We sought to determine the incidence of VTE in each of the following ethnic groups Caucasians, Africans, Asians, and Hispanics. Methods A systematic literature search strategy was used to identify potential studies in MEDLINE, EMBASE, and CENTRAL using an OVID interface. The methodological quality of eligible studies was assessed according to Newcastle-Ottawa Quality Assessment Scale. The primary outcome measure was to identify the incidence/prevalence of VTE of each ethnic group available for the study in the context of a population based study. Results Out of 3418 potential studies, 19 met our inclusion criteria (Table). Of these, 9 studies were population based studies: 5 reported VTE incidence per 100,000 person-years (PY), 2 measured the standardized incidence ratio, and 2 European studies assessed VTE rate according to country of origin but not ethnicity (data not shown). In addition, 7 studies measured the hospital incidence rate of VTE, and 3 assessed VTE prevalence. Data could not be pooled due to marked heterogeneity including varied periods of study. VTE incidence per 100,000 PY was found to be between 162 and 439 in Caucasians, 143 and 746 in Africans, 3.2 and 16.6 in Asians. Hospital incidence of VTE per 100,000 PY was found to be between 21 and 131 in Caucasians, 22 and 155 in Africans, 2 and 26 in Asians, 33.1 and 71 in American Indians/Alaskan Indians, and 9 in Hispanics. Conclusions Our findings suggest a wide variation in reported incidence rates for VTE among different ethnic groups, even within the same group. In general, studies in Asian populations suggest a lower incidence of VTE. A marked heterogeneity of study designs, population settings prevent drawing firm conclusions. A significant risk of bias cannot be excluded for several studies. Further studies assessing concurrently the risk of VTE among different ethnicities in the same geographical area are needed. Table 1. Summary of the included studies. Study Country Time Period f/u duration Sample size VTE incidence /Prevalence (95% CI) Zakai, 2014 US 439,090 person year 51,149 Zakai: ARIC US 1987-1996 15,792 (I) Cauc.: 166 (1.48-1.86) Afr.: 259 (2.21-3.03) Zakai: CHS US 1989-1997 5,888 (I) Cauc.: 439 (3.13-6.16) Afr.: 746 (4.68-11.90) Zakai: REGARDS, Southeast area US 2003-2007 30,239 (I) Cauc.: 162 (1.26-2.07) Afr.: 224 (1.72-2.92) Zakai: REGARDS, Rest of US US 2003-2007 30,239 (I) Cauc.: 205 (1.58-2.66) Afr.: 143 (1.02-2.00) Deitelzweig, 2010 US 2002 46,652 (P) per 100,000 persons Cauc.: M 457, F NA Afr.: M 584, F NA Hisp.: M 94, F 93 Others: M 329, F 345 2005 46,652 (P) per 100,000 persons Cauc.: M 643, F 446 Afr.: M 784, F 444 Hisp.: M 149, F 154 Others: M 285, F 297 DeMonaco, 2008 US 1997 37,892 (HI) Cauc.: 44 Afr.: 53 2001 37,892 (HI) Cauc.: 56 Afr.: 60 Heit, 2010 US 2003-2009 2,397 (P) N(%) Cauc.: Total= 1381 (69) Afr.: Total=272 (69) N(%) Cauc.: VTE = 551 (27) Afr.: VTE = 75 (19) Hooper, 2003 US 1980-1996 (HI) American Indians/Alaskan Indians: 33.1 Jang, 2011 Korea 2004 (I) Asians: VTE: 8.83, DVT: 3.91, PE: 3.74 2008 (I) Asians: VTE: 13.8, DVT: 5.31 , PE: 7.01 Kitamukai, 2003 Japan 2000 (I) Asians: 3.2 (29.2-33.9) Klatsky, 2000 US 1978-1994 1,822,302 total person years 128,934 (HI) Cauc.: 21 Afr.: 22 Asians: 2 Hisp.: 9 Others (unspecified): 15 Lee, 2010 Taiwan 2001 & 2002 11,566 person year Crude Incidence per 100,000 person year: Asians: VTE=15.9 Liu, 2002 China 1997-2000 (I) Asians: 16.6 Sakuma, 2009 Japan 2006 (I) Asians: PE= 6.19 (51.7- 72.1) DVT= 11.5 (98.2-132.9) Schneider, 2006 US 1998-2000 (HI) Cauc.: M 36.47 ; F 37.96 Afr.: M 53.64 ; F 61.53 Stein, Am J Med. 2004 US 1990-1999 (HI) Cauc.: VTE= 122 Afr.: VTE= 134 Asians: VTE= 23 Stein, Arch Intern Med. 2004 US 1996-2001 (HI) Cauc.: 131 Afr.: 155 American Indians and Alaskan Indians: 71 Tan, 2007 Singa-pore 1998-2001 271 pairs of cases and controls (P) N(%) Asians: 32.1% (29.0-35.3) White, 2005 US 1996 21,002 (SIR): Cauc.: 103 (101-105) Afr.: 138 (132-145) Asians: 29 (27-32) Hisp.: 61 (59-64) Others: 72 (65-80) White, 1998 US 1991-1994 17991 (SIR): Cauc.: 23 Afr.: 29.3 Asians: 6 Hisp.: 13.9 Abbreviations. f/u: follow up; CI: confidence interval; (I): incidence per 100,000 PY; (P): prevalence; (HI): Hospital Incidence per 100,000 PY; (SIR): Standardized Incidence Rate; M:male; F: female; N: total number. Cauc. Caucasians, Afr. Africans, Hisp. hispanics Disclosures Lazo-Langner: Pfizer: Honoraria; Bayer: Honoraria.

Sign in / Sign up

Export Citation Format

Share Document